TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
THERMO FISHER SCIENTIFIC INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Jul 31, 2026
$679.38−10.62 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $252.05B
- P/E (TTM)
- 36.6
- Dividend yield
- 0.25%
THERMO FISHER SCIENTIFIC INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | $6.69B | $6.04B | $6.38B | $5.97B | $6.00B | $5.64B | $5.94B | $5.74B | – | – | – | – | 55.8% | +11.6% |
| Life Sciences Solutions | $2.82B | $2.64B | $2.95B | $2.59B | $2.50B | $2.34B | $2.60B | $2.39B | $2.36B | $2.29B | $2.47B | $2.43B | 23.5% | +12.6% |
| Analytical Instruments | $1.85B | $1.72B | $2.22B | $1.89B | $1.73B | $1.72B | $2.19B | $1.81B | $1.78B | $1.69B | $2.04B | $1.75B | 15.4% | +6.9% |
| Specialty Diagnostics | $1.21B | $1.14B | $1.22B | $1.17B | $1.13B | $1.15B | $1.16B | $1.13B | $1.12B | $1.11B | $1.11B | $1.08B | 10.0% | +6.3% |
| Laboratory Products and Biopharma Services | – | – | – | – | – | $5.60B | $5.78B | $5.74B | $5.76B | $5.69B | $5.57B | $5.73B | – | – |
| Laboratory Products and Biopharma Services | – | – | – | – | $5.95B | – | – | – | $5.72B | – | – | – | – | – |
| Genetic sciences | – | – | – | – | – | $677.00M | – | – | – | $637.00M | – | – | – | – |
| Microbiology | – | – | – | – | – | $152.00M | – | – | – | $153.00M | – | – | – | – |
| Chemical analysis | – | – | – | – | – | $286.00M | – | – | – | $320.00M | – | – | – | – |
| Laboratory products | – | – | – | – | – | $582.00M | – | – | – | $624.00M | – | – | – | – |
| Electron microscopy | – | – | – | – | – | $659.00M | – | – | – | $579.00M | – | – | – | – |
| Research and safety market channel | – | – | – | – | – | $1.73B | – | – | – | $1.71B | – | – | – | – |
| Clinical diagnostics | – | – | – | – | – | $263.00M | – | – | – | $263.00M | – | – | – | – |
| Chromatography and mass spectrometry | – | – | – | – | – | $773.00M | – | – | – | $789.00M | – | – | – | – |
| Biosciences | – | – | – | – | – | $993.00M | – | – | – | $1.06B | – | – | – | – |
| Pharma services | – | – | – | – | – | $1.61B | – | – | – | $1.58B | – | – | – | – |
| ImmunoDiagnostics | – | – | – | – | – | $217.00M | – | – | – | $212.00M | – | – | – | – |
| Transplant diagnostics | – | – | – | – | – | $113.00M | – | – | – | $106.00M | – | – | – | – |
| Clinical research | – | – | – | – | – | $1.94B | – | – | – | $2.03B | – | – | – | – |
| Bio Production | – | – | – | – | – | $671.00M | – | – | – | $590.00M | – | – | – | – |
| Healthcare market channel | – | – | – | – | – | $474.00M | – | – | – | $438.00M | – | – | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences Solutions | $1.04B | $954.00M | $1.05B | $968.00M | $919.00M | $834.00M | $952.00M | $845.00M | $865.00M | $840.00M | $895.00M | $872.00M | +13.3% |
| Laboratory Products and Biopharma Services | $936.00M | $778.00M | $925.00M | $868.00M | $825.00M | $731.00M | $828.00M | $773.00M | – | – | – | – | +13.5% |
| Analytical Instruments | $424.00M | $355.00M | $583.00M | $429.00M | $325.00M | $399.00M | $666.00M | $451.00M | $439.00M | $400.00M | $587.00M | $468.00M | +30.5% |
| Specialty Diagnostics | $334.00M | $313.00M | $324.00M | $321.00M | $306.00M | $304.00M | $273.00M | $293.00M | $299.00M | $294.00M | $264.00M | $283.00M | +9.2% |
| Laboratory Products and Biopharma Services | – | – | – | – | – | $731.00M | $828.00M | $773.00M | $745.00M | $744.00M | $804.00M | $937.00M | – |
| Laboratory Products and Biopharma Services | – | – | – | – | $825.00M | – | – | – | $745.00M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $6.82B | $6.28B | $7.25B | $6.49B | $6.25B | $5.98B | $6.77B | $6.15B | $6.16B | $5.96B | $6.41B | $6.16B | 56.9% | +9.2% |
| Service revenues | $5.17B | $4.73B | $4.97B | $4.63B | $4.61B | $4.38B | $4.63B | $4.45B | $4.38B | $4.39B | $4.48B | $4.42B | 43.1% | +12.3% |
| Consumables | $5.07B | – | – | – | $4.61B | – | – | – | – | – | – | – | 42.3% | +10.1% |
| Instruments | $1.75B | – | – | – | $1.64B | – | – | – | – | – | – | – | 14.6% | +6.4% |
| Consumables | – | $4.72B | $5.03B | $4.68B | $4.61B | $4.35B | $4.52B | $4.38B | $4.36B | $4.33B | $4.37B | $4.29B | – | – |
| Instruments | – | $1.56B | $2.22B | $1.81B | $1.64B | $1.63B | $2.25B | $1.77B | $1.80B | $1.63B | $2.04B | $1.87B | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $6.15B | $5.71B | $6.11B | $5.69B | $5.72B | $5.51B | $5.86B | $5.59B | $5.53B | $5.52B | $5.60B | $5.67B | 51.3% | +7.5% |
| Europe | $3.31B | $2.96B | $3.37B | $3.01B | $2.83B | $2.62B | $2.89B | $2.69B | $2.66B | $2.62B | $2.84B | $2.64B | 27.6% | +17.0% |
| Asia-Pacific | $2.10B | $1.97B | $2.28B | $2.01B | $1.92B | $1.89B | $2.20B | $1.92B | $1.97B | $1.86B | $2.07B | $1.91B | 17.5% | +9.6% |
| Other regions | $430.00M | $372.00M | $462.00M | $415.00M | $383.00M | $337.00M | $439.00M | $397.00M | $379.00M | $346.00M | $367.00M | $350.00M | 3.6% | +12.3% |
| United States | – | – | – | – | – | – | $5.68B | $5.41B | $5.35B | $5.32B | $5.41B | $5.49B | – | – |
| Other | – | – | – | – | – | – | $5.72B | $5.19B | $5.19B | $5.02B | $5.48B | $5.08B | – | – |
From the segment and revenue-disaggregation notes of Thermo Fisher Scientific's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.